These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 38100544)

  • 1. Acquisition of suppressive function by conventional T cells limits antitumor immunity upon T
    Whiteside SK; Grant FM; Alvisi G; Clarke J; Tang L; Imianowski CJ; Zhang B; Evans AC; Wesolowski AJ; Conti AG; Yang J; Lauder SN; Clement M; Humphreys IR; Dooley J; Burton O; Liston A; Alloisio M; Voulaz E; Langhorne J; Okkenhaug K; Lugli E; Roychoudhuri R
    Sci Immunol; 2023 Dec; 8(90):eabo5558. PubMed ID: 38100544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling.
    Elwenspoek MM; Thom H; Sheppard AL; Keeney E; O'Donnell R; Jackson J; Roadevin C; Dawson S; Lane D; Stubbs J; Everitt H; Watson JC; Hay AD; Gillett P; Robins G; Jones HE; Mallett S; Whiting PF
    Health Technol Assess; 2022 Oct; 26(44):1-310. PubMed ID: 36321689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B7H6 is the predominant activating ligand driving natural killer cell-mediated killing in patients with liquid tumours: evidence from clinical, in silico, in vitro, and in vivo studies.
    Lee S; Chae SJ; Jang IH; Oh SC; Kim SM; Lee SY; Kim JH; Ko J; Kim HJ; Song IC; Kim JK; Kim TD
    EBioMedicine; 2024 Dec; 110():105459. PubMed ID: 39579618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective depletion of tumor-infiltrating regulatory T cells with BAY 3375968, a novel Fc-optimized anti-CCR8 antibody.
    Roider HG; Hoff S; Tseng SY; Berndt S; Trautwein M; Filarsky K; Gritzan U; Camps J; Nadler WM; Grudzinska-Goebel J; Ellinger P; Pesch T; Soon CF; Geyer M; Gluske K; Stelte-Ludwig B; Gorjánácz M
    Clin Exp Med; 2024 Jun; 24(1):122. PubMed ID: 38856863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HSP90 Inhibitor Pimitespib Targets Regulatory T Cells in the Tumor Microenvironment.
    Tsuge A; Watanabe S; Kawazoe A; Togashi Y; Itahashi K; Masuda M; Sai A; Takei S; Muraoka H; Ohkubo S; Sugiyama D; Yan Y; Fukuoka S; Doi T; Shitara K; Koyama S; Nishikawa H
    Cancer Immunol Res; 2024 Nov; ():. PubMed ID: 39602577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indirubin induces tolerogenic dendritic cells via aryl hydrocarbon receptor activation and ameliorates allergic asthma in a murine model by expanding Foxp3-expressing regulatory T cells.
    Chuang HC; Chuang KJ; Cheng PC; Hsieh CL; Fan YY; Lee YL
    Phytomedicine; 2024 Dec; 135():156013. PubMed ID: 39270571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline.
    Reece D; Imrie K; Stevens A; Smith CA;
    Curr Oncol; 2006 Oct; 13(5):160-72. PubMed ID: 22792013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human airway macrophages are metabolically reprogrammed by IFN-γ resulting in glycolysis-dependent functional plasticity.
    Cox DJ; Connolly SA; Ó Maoldomhnaigh C; Brugman AAI; Sandby Thomas O; Duffin E; Gogan KM; Ó Gallchobhair O; Murphy DM; O'Rourke SA; O'Connell F; Nadarajan P; Phelan JJ; Gleeson LE; Basdeo SA; Keane J
    Elife; 2024 Dec; 13():. PubMed ID: 39620891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic Immune Activation in Systemic Lupus Erythematosus and the Autoimmune PTPN22 Trp
    Ferreira RC; Castro Dopico X; Oliveira JJ; Rainbow DB; Yang JH; Trzupek D; Todd SA; McNeill M; Steri M; Orrù V; Fiorillo E; Crouch DJM; Pekalski ML; Cucca F; Tree TI; Vyse TJ; Wicker LS; Todd JA
    Front Immunol; 2019; 10():2606. PubMed ID: 31781109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Boosting antitumor immunity in breast cancers: Potential of adjuvants, drugs, and nanocarriers.
    Chen P; Ren L; Guo Y; Sun Y
    Int Rev Immunol; 2024 Nov; ():1-24. PubMed ID: 39611269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergizing autophagic cell death and oxaliplatin-induced immunogenic death by a self-delivery micelle for enhanced tumor immunotherapy.
    Deng T; Chen D; Chen F; Xu C; Zhang Q; Li M; Wang Y; He Z; Li M; He Q
    Acta Biomater; 2024 Dec; 190():548-559. PubMed ID: 39426655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Icariin promoted ferroptosis by activating mitochondrial dysfunction to inhibit colorectal cancer and synergistically enhanced the efficacy of PD-1 inhibitors.
    Haoyue W; Kexiang S; Shan TW; Jiamin G; Luyun Y; Junkai W; Wanli D
    Phytomedicine; 2024 Nov; 136():156224. PubMed ID: 39642461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T
    Lauten TH; Elkhatib SK; Natour T; Reed EC; Jojo CN; Case AJ
    Brain Behav Immun; 2025 Jan; 123():1061-1070. PubMed ID: 39542072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-17 Producing T to Foxp3
    Park JS; Song AY; Bae JY; Han JW; Kim TH; Kim CJ; Lee SK
    Am J Reprod Immunol; 2024 Nov; 92(5):e70020. PubMed ID: 39584290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH
    Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cell-, interleukin-12-, and gamma interferon-driven viral clearance in measles virus-infected brain tissue.
    Stubblefield Park SR; Widness M; Levine AD; Patterson CE
    J Virol; 2011 Apr; 85(7):3664-76. PubMed ID: 21270150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiation fate of a stem-like CD4 T cell controls immunity to cancer.
    Cardenas MA; Prokhnevska N; Sobierajska E; Gregorova P; Medina CB; Valanparambil RM; Greenwald R; DelBalzo L; Bilen MA; Joshi SS; Narayan VM; Master VA; Sanda MG; Kissick HT
    Nature; 2024 Dec; 636(8041):224-232. PubMed ID: 39443797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.
    Edwards SJ; Karner C; Jhita T; Barton S; Marceniuk G; Yiu ZZN; Wittmann M
    Health Technol Assess; 2024 Jan; 28(4):1-113. PubMed ID: 38343072
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.